U.S. General Merchandise and Department Stores Stock News

NYSE:TT
NYSE:TTBuilding

Trane Technologies (TT) Beat Expectations And Raised Guidance, Is The Stock Still Cheap?

Trane Technologies (TT) stock is in focus after the company paired strong quarterly results with a new collaboration with Eaton that targets power and cooling needs for AI focused data centers. At a share price of $454.31, Trane Technologies has seen some short term share price softness with a 1 day return that declined 1.96% and a 30 day share price return that declined 3.34%. However, the year to date share price return of 14.15% and a 3 year total shareholder return of 127.54% point to...
NasdaqGS:INDV
NasdaqGS:INDVPharmaceuticals

Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight

Indivior Pharmaceuticals (INDV) is back on investor radars after fresh analyst research highlighted a projected 46.4% EPS increase for this year and a 2.7% uplift in current year earnings estimates over the past month. Despite the upbeat earnings outlook, Indivior Pharmaceuticals’ recent share price momentum has cooled, with the stock down 13.88% on a 30 day share price return basis and 6.56% over 7 days, even though the 1 year total shareholder return of 47.82% points to stronger longer term...
NasdaqGS:ENSG
NasdaqGS:ENSGHealthcare

Ensign Group (ENSG) Lifted Its Outlook, Is The Premium Already Priced In?

Ensign Group (ENSG) is back in focus after reporting second quarter 2026 adjusted EPS of US$1.92, beating estimates, lifting its full year revenue and EPS outlook, and pairing results with buybacks and dividends. Ensign Group’s latest results land after a volatile few months for the stock, with recent short seller allegations and securities investigations triggering sharp swings and a share price of US$173.54 that is down over the past month but still higher on a 90 day share price return...
NasdaqGS:MQ
NasdaqGS:MQDiversified Financial

Marqeta (MQ), What Is Behind The Fresh Attention?

Marqeta (MQ) stock is in focus after the company announced on August 25, 2026, that Eugenia Gibbons will become Chief Product Officer. This may signal a potential shift in product priorities and execution. Marqeta shares trade at US$16.21 and recent moves have been mixed, with a 7 day share price return of 2.59% but a 30 day share price return that is down 10.29%. These shorter term swings sit against a 1 year total shareholder return that has declined 36.38% and a 5 year total shareholder...
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

RUM Group (RUM) On Its $13.7b GPU Deal And The Fair Value Debate

RUM Group (RUM) recently disclosed a six year, roughly US$13.70b commercial agreement for GPU services tied to its planned Maysville, Georgia facility, with customer warrants linking future equity issuance to AI infrastructure usage. RUM Group's latest share price of US$9.43 comes after strong short term momentum, with a 30 day share price return of 56.38% and a year to date share price return of 48.04%. However, the 1 year total shareholder return of 27.09% and 5 year total shareholder...
NasdaqGS:BHF
NasdaqGS:BHFInsurance

Higher Long Term Yields Put These US Insurance Stocks In Focus

Long term bond yields are pushing to decade highs, inflation is sitting at 3.4% against a 2% Fed target, and a new Fed chair who avoids clear forward guidance is keeping markets on edge. That mix can punish some stocks while opening different types of opportunities for others. This article explains how that backdrop relates to three U.S. insurance and annuity providers that may be especially exposed to the news. The stocks covered below are only a sample, and the full screen surfaced 20 more...
NYSE:OSK
NYSE:OSKMachinery

Oshkosh (OSK) Could Be 6% Below Fair Value On Earnings Beat And Reset Guidance

Oshkosh earnings beat and guidance reset Oshkosh (OSK) recently reported second quarter 2026 adjusted earnings that topped analyst expectations despite a year over year decline, while raising its full year sales outlook and trimming earnings guidance on slower fire truck production. Against this backdrop, Oshkosh’s share price has risen 20.55% over the past 90 days and 18.52% year to date to US$156.71, while the 1 year total shareholder return of 11.18% and 3 year total shareholder return of...
NasdaqGS:VECO
NasdaqGS:VECOSemiconductor

Why Veeco Instruments (VECO) Could Be 22% Undervalued On Growth Expectations

Veeco Instruments (VECO) has drawn fresh interest after recent trading data showed a 1 day gain of 1.7% and a year to date return of 53.7%. This performance has put its semiconductor exposure back in focus. At a latest share price of $46.95, Veeco Instruments has seen momentum cool in recent months, with the share price down 18.6% over the past 90 days. However, the year-to-date share price return of 53.7% and 1-year total shareholder return of 88.5% still point to a strong overall run that...
NYSE:ACN
NYSE:ACNIT

Accenture (ACN) Following The COMWARE Deal And The Debate Over Fair Value

Accenture (ACN) recently agreed to acquire Japanese technology services provider COMWARE, adding more than 180 professionals to support Accenture Edge, its mid market focused business serving companies with AI, data, and cloud solutions. The COMWARE deal comes as Accenture’s share price has rallied recently, with a 1 month share price return of 13.8% and a 7 day share price return of 3.3% taking the stock to US$187.38. However, the year to date share price return is still down 27.9% and the 1...
NYSE:MAIN
NYSE:MAINCapital Markets

Is Main Street Capital (MAIN) Fairly Valued As Supplemental Dividends Keep Coming?

Main Street Capital (MAIN) has drawn fresh attention after confirming another quarterly supplemental dividend of $0.30 per share in 2026, along with its monthly payouts, and signaling plans for an additional significant supplemental dividend in December. Recent dividend news comes after a strong 90-day share price return of 14.41% to US$58.59, even though the year to date share price return is down 5.12%. Over a longer stretch, Main Street Capital’s 3-year total shareholder return of 84.61%...
NYSE:AMC
NYSE:AMCEntertainment

AMC Entertainment (AMC) Edges Toward Positive Free Cash Flow Is Its Debt Strategy Reframing the Story?

Earlier this week, AMC Entertainment Holdings said it is edging closer to sustained positive free cash flow, estimating it needs an industrywide domestic box office of about US$10.40 billion to reach that goal, helped by record adjusted EBITDA, stronger per-patron profitability, and lower interest costs. An important angle is that AMC’s recent refinancing and debt-repayment efforts are expected to cut annual cash interest expense, meaning the box-office level required to support ongoing...
NasdaqGS:MBX
NasdaqGS:MBXPharmaceuticals

MBX Biosciences (MBX), Why Is It Getting So Much Attention Now?

MBX Biosciences (MBX) has reached a key clinical milestone with the first patient now dosed in its pivotal global Phase 3 oPTimize trial of once-weekly canvuparatide for chronic hypoparathyroidism. This step anchors current investor attention. For context, MBX Biosciences shares now trade at US$66.39, with a 30-day share price return of 10.54% and a 90-day share price return of 110.96%. The 1-year total shareholder return of 365.24% points to strong momentum as this Phase 3 trial gets...
NYSE:UNFI
NYSE:UNFIConsumer Retailing

Fresh Produce Stocks Retail Investors May Be Missing Before Canada Tariffs Hit

With Canada preparing 15% to 50% retaliatory tariffs on U.S. goods and Arizona’s US$676 million export link to Canadian buyers under pressure, the fresh produce trade now sits at the crossroads of politics and profit. For investors, that creates potential mispricing as the market weighs tariff risk against long term demand for foodservice and distribution. This article walks through 3 stocks exposed to this news and explains why they may warrant closer attention before Sept. 8. The stocks...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Tempus AI (TEM) Is Up 6.1% After New FDA-Cleared ECG PH Tool - Has The Bull Case Changed?

On 24 August 2026, Tempus AI received FDA 510(k) clearance for Tempus ECG-PH, an AI tool that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension in symptomatic patients over 40 without a known history of the disease. This third FDA-cleared cardiovascular device extends Tempus AI’s AI-enabled diagnostics portfolio into pulmonary hypertension, a hard-to-diagnose condition affecting a meaningful share of older adults. We’ll now examine how this new FDA-cleared...
NYSE:NPKI
NYSE:NPKITrade Distributors

NPK International (NPKI) Stock Climbed, What Is Driving Attention Today?

NPK International (NPKI) recently completed its rebranding from Newpark Resources Inc. The stock now reflects a clearer focus on temporary worksite access solutions that span power transmission, energy, and broader infrastructure services. NPK International’s share price has seen mixed momentum in recent months, with a 1-day share price return of 2.81% and a 30-day share price return of 4.71%, while the 90-day share price return is down 6.68%. At the same time, the stock’s longer history...
NasdaqGS:OKTA
NasdaqGS:OKTAIT

US Stock Market Today: S&P 500 Futures Climb On Steady Inflation And Spending Data

The Morning Bull - US Market Morning Update Friday, Aug, 28 2026 US Market stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.5% and Nasdaq-100 futures gaining more than 1%. The move comes after US durable goods orders rose 1.1% in July, which suggests companies are still spending on big ticket items like planes and machinery. At the same time, the PCE price index, a key inflation gauge watched by the Federal Reserve, increased 0.2% in July and is running...
NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Innodata (INOD) Stock Looks Rich On Earnings But Strong On Returns

Innodata has delivered very strong share price gains over the past five years, yet current valuation checks point to a stock that screens as expensive rather than a clear bargain. After such a long run, investors now have to weigh those historic returns against what the current price implies for the next leg of the story. Innodata has returned about 6.3x over 5 years, which puts extra focus on whether the current price already embeds very optimistic expectations. Recent leadership changes...
NYSE:AA
NYSE:AAMetals and Mining

How Investors Are Reacting To Alcoa (AA) Expanding Into Gallium At Its Wagerup Refinery

Alcoa Corporation recently held a groundbreaking ceremony for a new gallium production plant at its Wagerup alumina refinery in Western Australia, a project backed by government and industry partners from Australia, Japan and the United States and expected to support both construction and ongoing local jobs. The project’s focus on gallium, a critical mineral used in high-tech applications, underlines Alcoa’s expanding role in critical mineral supply chains alongside its core aluminum...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Old National Bancorp (ONB) Expanded With Bremer Bank, Is The Stock Still Cheap?

How Old National Bancorp Stock Has Been Trading Old National Bancorp (ONB) has drawn attention after a mixed stretch of recent returns. The stock is up slightly over the past week, roughly flat over the month, and higher over the past 3 months and year to date. At a share price of US$25.85, Old National Bancorp has delivered a 14.63% year to date share price return. Its 1 year total shareholder return of 16.35% and 3 year total shareholder return of 83.05% point to momentum that has built...
NasdaqGS:FLNC
NasdaqGS:FLNCElectrical

Will UBS’s Shift to Neutral on Loss-Making Fluence Energy (FLNC) Change Its Risk Narrative?

Earlier this week, UBS upgraded Fluence Energy’s stock rating from Sell to Neutral, signaling a shift in analyst stance despite the company’s continued loss-making and cash-burning profile. This change in sentiment stands out because it comes even as Fluence Energy’s negative EPS and constrained access to capital remain key concerns for cautious investors. We’ll now examine how UBS’s shift to a Neutral rating influences Fluence Energy’s investment narrative, particularly around risk...
NYSE:ROK
NYSE:ROKElectrical

Is Rockwell Automation’s New AI Support Push a Signal on Its Services Strategy for ROK?

Rockwell Automation recently launched TechConnectIQ Support, a 24x7 remote support offering for North American single-site contract customers, featuring AI-enabled tools, three-tier coverage, and improved visibility through the myRockwellAutomation TechConnect hub. The move highlights how Rockwell is aiming to deepen customer relationships by shifting more of its automation expertise into always-available, digitally delivered services. Next, we’ll explore how this enhanced remote support and...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Can Manhattan Associates (MANH) Justify Its Price As Strong Earnings Lift Guidance?

Manhattan Associates (MANH) has drawn fresh attention after reporting better than expected second quarter 2026 earnings and revenue, and raising full year guidance for total and cloud revenue, which gives investors new information to assess the stock. The recent earnings surprise sits alongside strong share price momentum for Manhattan Associates, with a 90 day share price return of 49.12% and a 30 day share price return of 33.06%, while the 1 year total shareholder return of 2.43% shows much...
NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Does Morningstar’s Gemini Integration Redefine Its Data-Monetization Edge for Investors (MORN)?

Morningstar and its subsidiary PitchBook previously announced upcoming Model Context Protocol integrations with Google Cloud’s Gemini Enterprise for Financial Services, bringing their public and private market intelligence directly into Gemini’s AI-powered workflows for eligible institutional users. The move effectively embeds Morningstar and PitchBook as core, source-attributed data and research providers inside Gemini Enterprise, potentially reshaping how professionals conduct investment...
NasdaqGS:SRPT
NasdaqGS:SRPTBiotechs

Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes

Sarepta Therapeutics (SRPT) is back in focus after investors reacted to expectations for late 2026 clinical data in facioscapulohumeral muscular dystrophy and myotonic dystrophy, alongside developments in its Duchenne therapy Elevidys and a competitor setback. Sarepta Therapeutics' recent 1 day share price return of 10.95% and 30 day share price return of 39.92% suggest momentum has picked up as traders react to the Elevidys update and reduced competition. However, the 3 year total...